hepatocellular carcinoma Archives

Home hepatocellular carcinoma

Second-line treatment options in hepatocellular carcinoma

Donatella Marino MD, Clizia Zichi MD, Marco Audisio MD, Elisa Sperti MD, Massimo Di Maio MD

Article Type

Review

Published

10 Apr 2019

This review discusses the evidence on second-line options for hepatocellular carcinoma, focusing on the latest results that are currently refining the treatment scenario.

Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications

Nicola Personeni MD, Tiziana Pressiani MD, Armando Santoro MD, Lorenza Rimassa MD

Article Type

Review

Published

27 Jun 2018

Over the past ten years, sorafenib has been the only systemic agent approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) and in a second-line setting, most investigational drugs have failed to provide better survival outcomes than placebo. However, in 2016, data from the RESORCE trial, a phase 3 study evaluating regorafenib in HCC patients who experience disease progression after first-line treatment with sorafenib, have shown a 2.8-month median survival benefit over placebo (10.6 versus 7.8 months).